Philip Paty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philip Paty has a total of 418 co-authors. Here are the top co-authors by number of shared publications:
- Martin Weiser
Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA
28 shared publications - Julio Garcia-Aguilar
Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
24 shared publications - Jesse Joshua Smith
Department of Surgery, Colorectal Surgery Service, Memorial Sloan Kettering Cancer Center, New York, USA
21 shared publications - Jinru Shia
Memorial Sloan Kettering Cancer Center
20 shared publications - Leonard B. Saltz
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
18 shared publications - Garrett M. Nash
Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
16 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Springer Nature in International Journal of Colorectal Disease
Primary tumor site is associated with oncological outcomes after surgical resection of pT2 colorectal cancer: a retrospective study with 10-year follow-up
Purpose: To evaluate long-term oncologic outcomes of pT2 colorectal cancer after upfront resection, based on tumor location within the large bowel. Methods: This retrospective cohort study included patients with pT2 colorectal adenocarcinoma treated with upfront surgery at a referral cancer center between 1990–2007. Outcomes included lymph node metastasis (LNM), recurrence, and disease-specific survival by tumor location. Results: 567 patients with pT2 colorectal adenocarcinoma were identified: 289 (51%) in the rectum (R), 112 (20%) in the left colon (LC), and 166 (29%) in the right colon (RC). Rates of LNM were higher in the R (26%) and LC (21%) compared to the RC (11%); adjusted ORs of 2.05 (R vs RC) and 2.01 (LC vs RC). 45 patients developed recurrence (10 local, 35 distant); 36 in rectal primaries, with a median follow-up of 120 months. Five-year cumulative incidence of recurrence was 1.3% (95%CI: 0.3–4.1), 4.6% (95%CI: 1.7–9.7) and 11% (95%CI: 7.4–15) for RC, LC, and R tumors respectively ( p < 0.001), with no significant interaction with LN status ( p interaction = 0.66). No significant association was observed between LNM and recurrence (HR 1.25, 95%CI 0.63–2.46, p = 0.5). Ten-year cumulative incidence of disease-specific death for RC, LC and R tumors was 0%, 4.3% (95%CI: 1.4–9.9), and 11.0% (95%CI: 7.5–16.0), respectively, ( p < 0.001). Conclusion: Compared with resected pT2 colon cancer, resected pT2 rectal cancer was associated with significantly higher rates of recurrence and death for both node-negative and node-positive disease. These findings suggest that T2N0 rectal cancer may not be uniformly low risk. Better strategies to select T2 rectal cancer patients for neoadjuvant and adjuvant treatment are needed.
- 30 October 2026
- Published by Springer Nature in International Journal of Colorectal Disease
Open AccessPrimary tumor site is associated with oncological outcomes after surgical resection of pT2 colorectal cancer: a retrospective study with 10-year follow-up
Purpose: To evaluate long-term oncologic outcomes of pT2 colorectal cancer after upfront resection, based on tumor location within the large bowel. Methods: This retrospective cohort study included patients with pT2 colorectal adenocarcinoma treated with upfront surgery at a referral cancer center between 1990–2007. Outcomes included lymph node metastasis (LNM), recurrence, and disease-specific survival by tumor location. Results: 567 patients with pT2 colorectal adenocarcinoma were identified: 289 (51%) in the rectum (R), 112 (20%) in the left colon (LC), and 166 (29%) in the right colon (RC). Rates of LNM were higher in the R (26%) and LC (21%) compared to the RC (11%); adjusted ORs of 2.05 (R vs RC) and 2.01 (LC vs RC). 45 patients developed recurrence (10 local, 35 distant); 36 in rectal primaries, with a median follow-up of 120 months. Five-year cumulative incidence of recurrence was 1.3% (95%CI: 0.3–4.1), 4.6% (95%CI: 1.7–9.7) and 11% (95%CI: 7.4–15) for RC, LC, and R tumors respectively ( p < 0.001), with no significant interaction with LN status ( p interaction = 0.66). No significant association was observed between LNM and recurrence (HR 1.25, 95%CI 0.63–2.46, p = 0.5). Ten-year cumulative incidence of disease-specific death for RC, LC and R tumors was 0%, 4.3% (95%CI: 1.4–9.9), and 11.0% (95%CI: 7.5–16.0), respectively, ( p < 0.001). Conclusion: Compared with resected pT2 colon cancer, resected pT2 rectal cancer was associated with significantly higher rates of recurrence and death for both node-negative and node-positive disease. These findings suggest that T2N0 rectal cancer may not be uniformly low risk. Better strategies to select T2 rectal cancer patients for neoadjuvant and adjuvant treatment are needed.
- 29 October 2026
- Published by Wiley in Journal of Surgical Oncology
Changes in Multidisciplinary Management of Locally Advanced Rectal Cancer at a Comprehensive Cancer Center From 2015 to 2023
Background: Multidisciplinary management of locally advanced rectal cancer (LARC) has evolved rapidly over the past decade, guided by data from multiple prospective clinical trials. Methods: Changes in treatment of cT3‐4 or N+ rectal cancer at a comprehensive cancer center between 2015 and 2023 were analyzed retrospectively. Results: Of 1121 patients who received neoadjuvant therapy, 793 (71%) underwent active surveillance and 328 (29%) underwent surgery within 3 months. Treatments whose use increased from 2015 to 2023 included TNT with consolidation chemotherapy (from 10% to 81%), neoadjuvant chemotherapy alone (from 13% to 21%), immunotherapy or targeted therapy (from 0% to 10%), and oral capecitabine versus intravenous fluorouracil in combination with oxaliplatin (from 4% to 56%). Among patients who received TNT, nonoperative management with sustained clinical complete response rose from 38% to 50%. With more patients undergoing nonoperative management, the rate of pathologic complete response decreased from 22% to 8.3%. Robotic assistance was used in 88% of surgeries. Conclusions: The adoption of new diagnostic and treatment paradigms allows for longer intervals until surgery, more frequent use of active surveillance, and higher rates of organ preservation without compromising safety or oncologic outcomes.
- 29 October 2026
- Published by Wiley in Journal of Surgical Oncology
Changes in Multidisciplinary Management of Locally Advanced Rectal Cancer at a Comprehensive Cancer Center From 2015 to 2023
Background: Multidisciplinary management of locally advanced rectal cancer (LARC) has evolved rapidly over the past decade, guided by data from multiple prospective clinical trials. Methods: Changes in treatment of cT3‐4 or N+ rectal cancer at a comprehensive cancer center between 2015 and 2023 were analyzed retrospectively. Results: Of 1121 patients who received neoadjuvant therapy, 793 (71%) underwent active surveillance and 328 (29%) underwent surgery within 3 months. Treatments whose use increased from 2015 to 2023 included TNT with consolidation chemotherapy (from 10% to 81%), neoadjuvant chemotherapy alone (from 13% to 21%), immunotherapy or targeted therapy (from 0% to 10%), and oral capecitabine versus intravenous fluorouracil in combination with oxaliplatin (from 4% to 56%). Among patients who received TNT, nonoperative management with sustained clinical complete response rose from 38% to 50%. With more patients undergoing nonoperative management, the rate of pathologic complete response decreased from 22% to 8.3%. Robotic assistance was used in 88% of surgeries. Conclusions: The adoption of new diagnostic and treatment paradigms allows for longer intervals until surgery, more frequent use of active surveillance, and higher rates of organ preservation without compromising safety or oncologic outcomes.
- Open Access
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , E43
Publisher Correction: Progressive plasticity during colorectal cancer metastasis
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , E43
Open AccessPublisher Correction: Progressive plasticity during colorectal cancer metastasis
- Open Access
- 26 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma
Patients with anal squamous cell carcinoma (ASCC) who fail chemoradiation (CRT) have poor outcomes, underscoring the need for biomarkers to guide risk stratification. In a real-world two-center cohort of 84 adults with non-metastatic ASCC treated with curative-intent CRT, we prospectively evaluate a tumor-informed circulating tumor DNA (ctDNA) assay (SignateraTM, Natera). Here we show that across 647 plasma specimens, ctDNA is positive at pre-treatment in 79% (61/77), including 89% (24/27) with stage III disease. End-of-treatment ctDNA positivity identifies patients with inferior one-year outcomes: 63% overall survival, 44% progression-free survival, and 39% locoregional failure. Conversely, patients who were ctDNA-negative at baseline or who cleared ctDNA during-treatment have 100% locoregional failure-free survival. During surveillance, ctDNA re-emergence precedes clinical or radiographic relapse in every case. These findings support the consideration of ctDNA as a dynamic, treatment-responsive biomarker warranting prospective validation for risk-adapted surveillance and adjuvant therapy in ASCC.
- 26 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma
Patients with anal squamous cell carcinoma (ASCC) who fail chemoradiation (CRT) have poor outcomes, underscoring the need for biomarkers to guide risk stratification. In a real-world two-center cohort of 84 adults with non-metastatic ASCC treated with curative-intent CRT, we prospectively evaluate a tumor-informed circulating tumor DNA (ctDNA) assay (SignateraTM, Natera). Here we show that across 647 plasma specimens, ctDNA is positive at pre-treatment in 79% (61/77), including 89% (24/27) with stage III disease. End-of-treatment ctDNA positivity identifies patients with inferior one-year outcomes: 63% overall survival, 44% progression-free survival, and 39% locoregional failure. Conversely, patients who were ctDNA-negative at baseline or who cleared ctDNA during-treatment have 100% locoregional failure-free survival. During surveillance, ctDNA re-emergence precedes clinical or radiographic relapse in every case. These findings support the consideration of ctDNA as a dynamic, treatment-responsive biomarker warranting prospective validation for risk-adapted surveillance and adjuvant therapy in ASCC.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2)
Risk of Residual Cancer After Immediate Surgery or Nonoperative Management After Malignant Colorectal Polypectomy With High-Risk Features
PURPOSE: National guidelines recommend colorectal resection when pathology from a malignant colorectal polyp reveals high-risk features (HRFs). However, some patients opt to avoid surgery because of concerns about associated morbidity and potential impacts on quality of life, despite the risk of residual disease. METHODS: In this single-center cohort study of patients treated between 2015 and 2022, we retrospectively compared rates of residual disease between patients who underwent immediate surgery and patients managed nonoperatively after removal of a malignant polyp with HRFs. RESULTS: Of 336 patients who underwent a polypectomy in the colon (n = 226) or rectum (n = 110) and had at least one HRF, 208 (62%) underwent immediate surgery and 128 (38%) were managed nonoperatively. Residual disease was identified in 63 patients (19%), either at the time of immediate surgery or during surveillance in the nonoperative group. In the immediate surgery group, 51 (25%) patients had residual disease, including 19 (9%) with residual disease in the bowel wall and 39 (19%) in locoregional lymph nodes (LNs). In the nonoperative cohort group, 12 (9%) developed recurrence after polypectomy during surveillance, including 7 (6%) in the bowel wall and 5 (4%) in locoregional LNs. In the nonoperative group, all recurrences after polypectomy were successfully treated with salvage surgery (n = 6) or chemoradiotherapy (n = 6). Distant metastases occurred in 2% of patients. CONCLUSION: The risk of residual disease after removal of a malignant polyp with HRFs approaches 20%. Patients who are concerned about the potential morbidity of surgery and its impact on postoperative quality of life should be counseled about this risk, as well as the availability of effective salvage treatments after nonoperative surveillance.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2)
Risk of Residual Cancer After Immediate Surgery or Nonoperative Management After Malignant Colorectal Polypectomy With High-Risk Features
PURPOSE: National guidelines recommend colorectal resection when pathology from a malignant colorectal polyp reveals high-risk features (HRFs). However, some patients opt to avoid surgery because of concerns about associated morbidity and potential impacts on quality of life, despite the risk of residual disease. METHODS: In this single-center cohort study of patients treated between 2015 and 2022, we retrospectively compared rates of residual disease between patients who underwent immediate surgery and patients managed nonoperatively after removal of a malignant polyp with HRFs. RESULTS: Of 336 patients who underwent a polypectomy in the colon (n = 226) or rectum (n = 110) and had at least one HRF, 208 (62%) underwent immediate surgery and 128 (38%) were managed nonoperatively. Residual disease was identified in 63 patients (19%), either at the time of immediate surgery or during surveillance in the nonoperative group. In the immediate surgery group, 51 (25%) patients had residual disease, including 19 (9%) with residual disease in the bowel wall and 39 (19%) in locoregional lymph nodes (LNs). In the nonoperative cohort group, 12 (9%) developed recurrence after polypectomy during surveillance, including 7 (6%) in the bowel wall and 5 (4%) in locoregional LNs. In the nonoperative group, all recurrences after polypectomy were successfully treated with salvage surgery (n = 6) or chemoradiotherapy (n = 6). Distant metastases occurred in 2% of patients. CONCLUSION: The risk of residual disease after removal of a malignant polyp with HRFs approaches 20%. Patients who are concerned about the potential morbidity of surgery and its impact on postoperative quality of life should be counseled about this risk, as well as the availability of effective salvage treatments after nonoperative surveillance.
- Open Access
Impact of Patient-Reported Outcome Monitoring via Recovery Tracker on Post-Discharge Outcomes After Colorectal Surgery: A Comparative Analysis Before and After Implementation
Background: Remote symptom monitoring via electronic platforms may identify patients at risk for unplanned acute care visits after surgery. Since 2016, the Memorial Sloan Kettering Cancer Center (MSKCC) has employed the Recovery Tracker (RT), a patient-reported outcome (PRO) system, for symptom monitoring after ambulatory procedures. In 2021, RT was extended to patients undergoing inpatient colorectal surgery. Objective: To evaluate the impact of RT implementation on urgent care utilization and readmission rates in patients undergoing elective inpatient colorectal surgery and to determine whether patient engagement with RT influences these outcomes. Methods: In this retrospective observational study at MSKCC, we compared patients undergoing elective colorectal surgery during the RT implementation period (March 2021–December 2022) to a historical control cohort (February 2019–February 2020). The primary outcome was a potentially unnecessary urgent care center (UCC) visits—defined as a visit not requiring inpatient admission. Secondary outcomes included 30-day readmission and survey engagement. Multivariable logistic regression was used for adjusted comparisons. Results: A total of 1941 patients in the RT cohort and 1206 in the control group met the inclusion criteria. The RT cohort had higher rates of UCC visits without admission (4.43% vs. 1.6%) and 30-day readmissions (9.74% vs. 6.88%). RT period surgery was independently associated with increased odds of UCC visits (OR 2.80, 95% CI 1.71–4.58, p < 0.0001) and readmissions (OR 1.43, 95% CI 1.09–1.88, p = 0.0098). Notably, RT users who completed at least one survey (70.2%) had significantly lower odds of readmission (OR 0.56, 95% CI 0.41–0.77, p = 0.0003) compared to non-responders. Discussion: Engagement with the RT system was associated with a 44% reduction in readmission risk, identifying non-responders as a vulnerable subgroup. While the overall rates of post-discharge care utilization increased after RT implementation, active participation in PRO reporting emerged as a protective factor. Conclusions: These findings highlight the need for strategies to promote engagement and support patients less likely to interact with remote monitoring tools. Non-response may signal barriers such as technological challenges or increased vulnerability, warranting proactive engagement strategies.
Open AccessImpact of Patient-Reported Outcome Monitoring via Recovery Tracker on Post-Discharge Outcomes After Colorectal Surgery: A Comparative Analysis Before and After Implementation
Background: Remote symptom monitoring via electronic platforms may identify patients at risk for unplanned acute care visits after surgery. Since 2016, the Memorial Sloan Kettering Cancer Center (MSKCC) has employed the Recovery Tracker (RT), a patient-reported outcome (PRO) system, for symptom monitoring after ambulatory procedures. In 2021, RT was extended to patients undergoing inpatient colorectal surgery. Objective: To evaluate the impact of RT implementation on urgent care utilization and readmission rates in patients undergoing elective inpatient colorectal surgery and to determine whether patient engagement with RT influences these outcomes. Methods: In this retrospective observational study at MSKCC, we compared patients undergoing elective colorectal surgery during the RT implementation period (March 2021–December 2022) to a historical control cohort (February 2019–February 2020). The primary outcome was a potentially unnecessary urgent care center (UCC) visits—defined as a visit not requiring inpatient admission. Secondary outcomes included 30-day readmission and survey engagement. Multivariable logistic regression was used for adjusted comparisons. Results: A total of 1941 patients in the RT cohort and 1206 in the control group met the inclusion criteria. The RT cohort had higher rates of UCC visits without admission (4.43% vs. 1.6%) and 30-day readmissions (9.74% vs. 6.88%). RT period surgery was independently associated with increased odds of UCC visits (OR 2.80, 95% CI 1.71–4.58, p < 0.0001) and readmissions (OR 1.43, 95% CI 1.09–1.88, p = 0.0098). Notably, RT users who completed at least one survey (70.2%) had significantly lower odds of readmission (OR 0.56, 95% CI 0.41–0.77, p = 0.0003) compared to non-responders. Discussion: Engagement with the RT system was associated with a 44% reduction in readmission risk, identifying non-responders as a vulnerable subgroup. While the overall rates of post-discharge care utilization increased after RT implementation, active participation in PRO reporting emerged as a protective factor. Conclusions: These findings highlight the need for strategies to promote engagement and support patients less likely to interact with remote monitoring tools. Non-response may signal barriers such as technological challenges or increased vulnerability, warranting proactive engagement strategies.
- Open Access
- 9 January 2025
- Published by Springer Nature in Nature
- Vol. 637 (8047) , E28
Author Correction: Progressive plasticity during colorectal cancer metastasis
- 9 January 2025
- Published by Springer Nature in Nature
- Vol. 637 (8047) , E28
Open AccessAuthor Correction: Progressive plasticity during colorectal cancer metastasis
- 18 November 2024
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 68 (3) , 300-307
Correlation Between Grade of Clinical Response to Neoadjuvant Therapy for Rectal Cancer and Oncologic Outcomes in the Era of Watch-and-Wait
BACKGROUND: The watch-and-wait strategy provides an opportunity to pursue nonoperative management in rectal cancer patients with clinical complete response after neoadjuvant therapy. The management of those with near-complete response remains controversial. OBJECTIVE: We assessed the oncologic outcomes of patients managed by watch-and-wait versus total mesorectal excision according to clinical response to neoadjuvant therapy. DESIGN: Retrospective cohort study. SETTINGS: Comprehensive cancer center in New York. PATIENTS: Patients with rectal adenocarcinoma diagnosed between January 2006 and December 2020. INTERVENTIONS: A watch-and-wait strategy of active surveillance was offered to patients if they achieved clinical complete response. Salvage surgery was used for watch-and-wait patients with local regrowth. Patients with an incomplete response underwent total mesorectal excision. MAIN OUTCOME MEASURES: Local regrowth rate, organ preservation rate, disease-free survival, and overall survival. RESULTS: Patients with rectal adenocarcinoma (n = 1230) were divided into 3 response cohorts—incomplete (n = 646), near-complete (n = 189), and complete (n = 395). Eighty-one patients (43%) in the near-complete group and 351 patients (89%) in the complete group entered watch-and-wait. Three-year local regrowth rates were 40% and 24% in the near-complete and complete response cohorts, respectively. The 5-year organ preservation rate was 53% in near-complete responders and 73% in complete responders. Five-year disease-free survival increased with greater clinical response to neoadjuvant therapy, with intermediate outcomes noted for patients with a near-complete (73%) compared to complete (82%) or incomplete (68%) response. Overall survival at 5 years was similar between the 3 cohorts (complete 90%, near-complete 86%, and incomplete 85%). LIMITATIONS: Retrospective nature. CONCLUSIONS: Greater clinical response to neoadjuvant therapy is associated with improved oncologic outcomes. Near-complete responders may avoid surgery and still achieve high organ preservation rates yet experience greater local regrowth rates than clinical complete response patients. Ongoing prospective trials integrating watch-and-wait after complete response as determined by uniform criteria will bolster the work to help treating physicians better select patients who qualify for active surveillance. See Video Abstract. CORRELACIÓN ENTRE EL GRADO DE RESPUESTA CLÍNICA A LA TERAPIA NEOADYUVANTE CONTRA EL CÁNCER DEL RECTO Y LOS RESULTADOS ONCOLÓGICOS EN LA ERA DE OBSERVAR Y ESPERAR: ANTECEDENTES: La estrategia de observar y esperar brinda la oportunidad de buscar un tratamiento no quirúrgico en pacientes con cáncer del recto con respuesta clínica completa después de la terapia neoadyuvante. El tratamiento de aquellos con respuesta casi completa sigue siendo controversial. OBJETIVO: Evaluamos los resultados oncológicos de los pacientes tratados con observar y esperar versus escisión mesorrectal total según la respuesta clínica a la terapia neoadyuvante. DISEÑO: Estudio de cohorte retrospectivo. CONFIGURACIÓN: Centro oncológico integral en Nueva York. PACIENTES: Pacientes con adenocarcinoma rectal diagnosticado entre enero de 2006 y diciembre de 2020. INTERVENCIONES: Se ofreció una estrategia de observar y esperar de vigilancia activa a los pacientes si lograban una respuesta clínica completa. Se utilizó cirugía de rescate para pacientes en observar y esperar con recrecimiento local. Los pacientes con una respuesta incompleta se sometieron a escisión mesorrectal total. PRINCIPALES MEDIDAS DE RESULTADO: Tasa de recrecimiento local, tasa de preservación de órganos, supervivencia libre de enfermedad y supervivencia general. RESULTADOS: Los pacientes con adenocarcinoma rectal (n = 1230) se dividieron en 3 cohortes de respuesta: incompleta (n = 646), casi completa (n = 189) y completa (n = 395). Ochenta y un (43%) pacientes en el grupo casi completo y 351 (89%) pacientes en el grupo completo ingresaron en observar y esperar. Las tasas de recrecimiento local a tres años fueron del 40% y 24% en las cohortes de respuesta casi completa y completa, respectivamente. La tasa de preservación de órganos a 5 años fue del 53% en los respondedores casi completos y del 73% en los respondedores completos. La supervivencia libre de enfermedad a cinco años aumentó con una mayor respuesta clínica a la terapia neoadyuvante con resultados intermedios observados para pacientes con una respuesta casi completa (73%) en comparación con la completa (82%) o incompleta (68%). La supervivencia global a los 5 años fue similar entre las tres cohortes (completa 90%, casi completa 86% e incompleta 85%). LIMITACIONES: Naturaleza retrospectiva. CONCLUSIÓN: Una mayor respuesta clínica a la terapia neoadyuvante se asocia con mejores resultados oncológicos. Los pacientes con respuesta casi completa pueden evitar la cirugía y aun así lograr altas tasas de preservación de órganos, pero experimentar mayores tasas de recrecimiento local que los pacientes con respuesta clínica completa. Los ensayos prospectivos en curso que integran observar y esperar después de la respuesta completa según lo determinado por criterios uniformes reforzarán el trabajo para ayudar a los médicos tratantes a seleccionar mejor a los pacientes que califican para la vigilancia activa. (Traducción—Dr. Aurian Garcia Gonzalez)
- 18 November 2024
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 68 (3) , 300-307
Correlation Between Grade of Clinical Response to Neoadjuvant Therapy for Rectal Cancer and Oncologic Outcomes in the Era of Watch-and-Wait
BACKGROUND: The watch-and-wait strategy provides an opportunity to pursue nonoperative management in rectal cancer patients with clinical complete response after neoadjuvant therapy. The management of those with near-complete response remains controversial. OBJECTIVE: We assessed the oncologic outcomes of patients managed by watch-and-wait versus total mesorectal excision according to clinical response to neoadjuvant therapy. DESIGN: Retrospective cohort study. SETTINGS: Comprehensive cancer center in New York. PATIENTS: Patients with rectal adenocarcinoma diagnosed between January 2006 and December 2020. INTERVENTIONS: A watch-and-wait strategy of active surveillance was offered to patients if they achieved clinical complete response. Salvage surgery was used for watch-and-wait patients with local regrowth. Patients with an incomplete response underwent total mesorectal excision. MAIN OUTCOME MEASURES: Local regrowth rate, organ preservation rate, disease-free survival, and overall survival. RESULTS: Patients with rectal adenocarcinoma (n = 1230) were divided into 3 response cohorts—incomplete (n = 646), near-complete (n = 189), and complete (n = 395). Eighty-one patients (43%) in the near-complete group and 351 patients (89%) in the complete group entered watch-and-wait. Three-year local regrowth rates were 40% and 24% in the near-complete and complete response cohorts, respectively. The 5-year organ preservation rate was 53% in near-complete responders and 73% in complete responders. Five-year disease-free survival increased with greater clinical response to neoadjuvant therapy, with intermediate outcomes noted for patients with a near-complete (73%) compared to complete (82%) or incomplete (68%) response. Overall survival at 5 years was similar between the 3 cohorts (complete 90%, near-complete 86%, and incomplete 85%). LIMITATIONS: Retrospective nature. CONCLUSIONS: Greater clinical response to neoadjuvant therapy is associated with improved oncologic outcomes. Near-complete responders may avoid surgery and still achieve high organ preservation rates yet experience greater local regrowth rates than clinical complete response patients. Ongoing prospective trials integrating watch-and-wait after complete response as determined by uniform criteria will bolster the work to help treating physicians better select patients who qualify for active surveillance. See Video Abstract. CORRELACIÓN ENTRE EL GRADO DE RESPUESTA CLÍNICA A LA TERAPIA NEOADYUVANTE CONTRA EL CÁNCER DEL RECTO Y LOS RESULTADOS ONCOLÓGICOS EN LA ERA DE OBSERVAR Y ESPERAR: ANTECEDENTES: La estrategia de observar y esperar brinda la oportunidad de buscar un tratamiento no quirúrgico en pacientes con cáncer del recto con respuesta clínica completa después de la terapia neoadyuvante. El tratamiento de aquellos con respuesta casi completa sigue siendo controversial. OBJETIVO: Evaluamos los resultados oncológicos de los pacientes tratados con observar y esperar versus escisión mesorrectal total según la respuesta clínica a la terapia neoadyuvante. DISEÑO: Estudio de cohorte retrospectivo. CONFIGURACIÓN: Centro oncológico integral en Nueva York. PACIENTES: Pacientes con adenocarcinoma rectal diagnosticado entre enero de 2006 y diciembre de 2020. INTERVENCIONES: Se ofreció una estrategia de observar y esperar de vigilancia activa a los pacientes si lograban una respuesta clínica completa. Se utilizó cirugía de rescate para pacientes en observar y esperar con recrecimiento local. Los pacientes con una respuesta incompleta se sometieron a escisión mesorrectal total. PRINCIPALES MEDIDAS DE RESULTADO: Tasa de recrecimiento local, tasa de preservación de órganos, supervivencia libre de enfermedad y supervivencia general. RESULTADOS: Los pacientes con adenocarcinoma rectal (n = 1230) se dividieron en 3 cohortes de respuesta: incompleta (n = 646), casi completa (n = 189) y completa (n = 395). Ochenta y un (43%) pacientes en el grupo casi completo y 351 (89%) pacientes en el grupo completo ingresaron en observar y esperar. Las tasas de recrecimiento local a tres años fueron del 40% y 24% en las cohortes de respuesta casi completa y completa, respectivamente. La tasa de preservación de órganos a 5 años fue del 53% en los respondedores casi completos y del 73% en los respondedores completos. La supervivencia libre de enfermedad a cinco años aumentó con una mayor respuesta clínica a la terapia neoadyuvante con resultados intermedios observados para pacientes con una respuesta casi completa (73%) en comparación con la completa (82%) o incompleta (68%). La supervivencia global a los 5 años fue similar entre las tres cohortes (completa 90%, casi completa 86% e incompleta 85%). LIMITACIONES: Naturaleza retrospectiva. CONCLUSIÓN: Una mayor respuesta clínica a la terapia neoadyuvante se asocia con mejores resultados oncológicos. Los pacientes con respuesta casi completa pueden evitar la cirugía y aun así lograr altas tasas de preservación de órganos, pero experimentar mayores tasas de recrecimiento local que los pacientes con respuesta clínica completa. Los ensayos prospectivos en curso que integran observar y esperar después de la respuesta completa según lo determinado por criterios uniformes reforzarán el trabajo para ayudar a los médicos tratantes a seleccionar mejor a los pacientes que califican para la vigilancia activa. (Traducción—Dr. Aurian Garcia Gonzalez)
- Top Cited PapersOpen Access
- 30 October 2024
- Published by Springer Nature in Nature
- Vol. 637 (8047) , 947-954
Progressive plasticity during colorectal cancer metastasis
As cancers progress, they become increasingly aggressive—metastatic tumours are less responsive to first-line therapies than primary tumours, they acquire resistance to successive therapies and eventually cause death1,2. Mutations are largely conserved between primary and metastatic tumours from the same patients, suggesting that non-genetic phenotypic plasticity has a major role in cancer progression and therapy resistance3–5. However, we lack an understanding of metastatic cell states and the mechanisms by which they transition. Here, in a cohort of biospecimen trios from same-patient normal colon, primary and metastatic colorectal cancer, we show that, although primary tumours largely adopt LGR5+ intestinal stem-like states, metastases display progressive plasticity. Cancer cells lose intestinal cell identities and reprogram into a highly conserved fetal progenitor state before undergoing non-canonical differentiation into divergent squamous and neuroendocrine-like states, a process that is exacerbated in metastasis and by chemotherapy and is associated with poor patient survival. Using matched patient-derived organoids, we demonstrate that metastatic cells exhibit greater cell-autonomous multilineage differentiation potential in response to microenvironment cues compared with their intestinal lineage-restricted primary tumour counterparts. We identify PROX1 as a repressor of non-intestinal lineage in the fetal progenitor state, and show that downregulation of PROX1 licenses non-canonical reprogramming.
- 30 October 2024
- Published by Springer Nature in Nature
- Vol. 637 (8047) , 947-954
Top Cited PapersOpen AccessProgressive plasticity during colorectal cancer metastasis
As cancers progress, they become increasingly aggressive—metastatic tumours are less responsive to first-line therapies than primary tumours, they acquire resistance to successive therapies and eventually cause death1,2. Mutations are largely conserved between primary and metastatic tumours from the same patients, suggesting that non-genetic phenotypic plasticity has a major role in cancer progression and therapy resistance3–5. However, we lack an understanding of metastatic cell states and the mechanisms by which they transition. Here, in a cohort of biospecimen trios from same-patient normal colon, primary and metastatic colorectal cancer, we show that, although primary tumours largely adopt LGR5+ intestinal stem-like states, metastases display progressive plasticity. Cancer cells lose intestinal cell identities and reprogram into a highly conserved fetal progenitor state before undergoing non-canonical differentiation into divergent squamous and neuroendocrine-like states, a process that is exacerbated in metastasis and by chemotherapy and is associated with poor patient survival. Using matched patient-derived organoids, we demonstrate that metastatic cells exhibit greater cell-autonomous multilineage differentiation potential in response to microenvironment cues compared with their intestinal lineage-restricted primary tumour counterparts. We identify PROX1 as a repressor of non-intestinal lineage in the fetal progenitor state, and show that downregulation of PROX1 licenses non-canonical reprogramming.
- 1 August 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2300233
Clinical Calculator for Predicting Freedom From Recurrence After Resection of Stage I-III Colon Cancer in Patients With Microsatellite Instability
PURPOSE: Outcome for patients with nonmetastatic, microsatellite instability (MSI) colon cancer is favorable: however, high-risk cohorts exist. This study was aimed at developing and validating a nomogram model to predict freedom from recurrence (FFR) for patients with resected MSI colon cancer. PATIENTS AND METHODS: Data from patients who underwent curative resection of stage I, II, or III MSI colon cancer in 2014-2021 (model training cohort, 384 patients, 33 events; median follow-up, 38.8 months) were retrospectively collected from institutional databases. Variables associated with recurrence in multivariable analysis were selected for inclusion in the clinical calculator. The calculator's predictive accuracy was measured with the concordance index and validated using data from patients who underwent treatment for MSI colon cancer in 2007-2013 (validation cohort, 164 patients, eight events; median follow-up, 84.8 months). RESULTS: T category and number of positive lymph nodes were significantly associated with recurrence in multivariable analysis and were selected for inclusion in the clinical calculator. The calculator's concordance index for FFR in the model training cohort was 0.812 (95% CI, 0.742 to 0.873), compared with 0.759 (95% CI, 0.683 to 0.840) for the staging schema of the eighth edition of the American Joint Committee on Cancer Staging Manual. The concordance index for the validation cohort was 0.744 (95% CI, 0.666 to 0.822), confirming robust predictive accuracy. CONCLUSION: Although in general patients with nonmetastatic MSI colon cancer had favorable outcome, patients with advanced T category and multiple metastatic lymph nodes had higher risk of recurrence. The clinical calculator identified patients with MSI colon cancer at high risk for recurrence, and this could inform surveillance strategies. In addition, the model could be used in trial design to identify patients suitable for novel adjuvant therapy.
- 1 August 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2300233
Clinical Calculator for Predicting Freedom From Recurrence After Resection of Stage I-III Colon Cancer in Patients With Microsatellite Instability
PURPOSE: Outcome for patients with nonmetastatic, microsatellite instability (MSI) colon cancer is favorable: however, high-risk cohorts exist. This study was aimed at developing and validating a nomogram model to predict freedom from recurrence (FFR) for patients with resected MSI colon cancer. PATIENTS AND METHODS: Data from patients who underwent curative resection of stage I, II, or III MSI colon cancer in 2014-2021 (model training cohort, 384 patients, 33 events; median follow-up, 38.8 months) were retrospectively collected from institutional databases. Variables associated with recurrence in multivariable analysis were selected for inclusion in the clinical calculator. The calculator's predictive accuracy was measured with the concordance index and validated using data from patients who underwent treatment for MSI colon cancer in 2007-2013 (validation cohort, 164 patients, eight events; median follow-up, 84.8 months). RESULTS: T category and number of positive lymph nodes were significantly associated with recurrence in multivariable analysis and were selected for inclusion in the clinical calculator. The calculator's concordance index for FFR in the model training cohort was 0.812 (95% CI, 0.742 to 0.873), compared with 0.759 (95% CI, 0.683 to 0.840) for the staging schema of the eighth edition of the American Joint Committee on Cancer Staging Manual. The concordance index for the validation cohort was 0.744 (95% CI, 0.666 to 0.822), confirming robust predictive accuracy. CONCLUSION: Although in general patients with nonmetastatic MSI colon cancer had favorable outcome, patients with advanced T category and multiple metastatic lymph nodes had higher risk of recurrence. The clinical calculator identified patients with MSI colon cancer at high risk for recurrence, and this could inform surveillance strategies. In addition, the model could be used in trial design to identify patients suitable for novel adjuvant therapy.